1 Title: White blood cells and severe COVID-19: a Mendelian randomization study 2 Yitang Sun¹, Jingqi Zhou^{1,2}, Kaixiong Ye^{1,3,*} 3 4 5 ¹ Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, 6 Athens, GA, USA ² School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 7 8 P.R. China ³ Institute of Bioinformatics, University of Georgia, Athens, GA, USA 9 10 11

* Address for Correspondence:

Dr. Kaixiong Ye 13

- 14 **Department of Genetics**
- University of Georgia 15
- 16 C220 Davison Life Sciences
- 120 East Green Street, Athens, GA 30602 17
- Office: 706-542-5898 18
- Fax: 706-542-3910 19
- 20 Email: Kaixiong.Ye@uga.edu

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Abstract Background: The pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly emerged to seriously threaten public health. We aimed to investigate whether white blood cell traits have potential causal effects on severe COVID-19 using Mendelian randomization (MR). Methods: To evaluate the causal associations between various white blood cell traits and severe COVID-19, we conducted a two-sample MR analysis with summary statistics from recent large genome-wide association studies. Results: Our MR results indicated potential causal associations of white blood cell count, myeloid white blood cell count, and granulocyte count with severe COVID-19, with odds ratios (OR) of 0.84 (95% CI: 0.72-0.98), 0.81 (95% CI: 0.70-0.94), and 0.84 (95% CI: 0.71-0.99), respectively. Increasing eosinophil percentage of white blood cells was associated with a higher risk of severe COVID-19 (OR: 1.22, 95% CI: 1.03-1.45). **Conclusions:** Our results suggest the potential causal effects of lower white blood cell count, lower myeloid white blood cell count, lower granulocyte count, and higher eosinophil percentage of white blood cells on an increased risk of severe COVID-19.

Key Words: COVID-19; white blood cells; eosinophil; Mendelian randomization

Background

Coronavirus disease 2019 (COVID-19) is caused by infection of a novel virus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS®CoV®2) [1]. SARS®CoV®2 has rapidly spread, causing damage or even death [2-4]. Besides age and gender, some pre-existing conditions are also well-known to be associated with an increased risk of severe COVID-19, such as cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and cancers [4-7]. Recently, genetic studies, including two genome-wide association studies (GWAS), have identified multiple genetic loci to be associated with the susceptibility and severity of COVID-19 [8-10]. However, causal risk factors for severe COVID-19 remain unclear. Identifying host factors predisposing individuals to severe COVID-19 is urgently needed to improve primary prevention and to develop treatment strategies.

Elevated white blood cell and neutrophil counts, and depleted lymphocyte count have been repeatedly observed in COVID-19 patients with severe outcomes, and neutrophil-to-lymphocyte ratio have been proposed as a prognostic biomarker [1, 11-14]. However, findings from recent observational studies are inconsistent and the exact roles of white blood cells and its various subtypes in severe COVID-19 remain elusive [15-17]. Most existing studies measured blood cell counts in patients with confirmed infection of SARS-CoV-2 and as a result, the hematological indices could have been modified by immune responses [18]. It is unknown if blood cell counts before infection are

associated with the risk of developing severe COVID-19. Even if white blood cells are measured before infection, they are influenced by many exogenous and endogenous factors (e.g., age, gender, disease status, and medications), which will confound the observational associations [19, 20]. No previous research has been able to interrogate the causal role of white blood cells in severe COVID-19.

While traditional observational associations often suffer from confounding, reverse causality, and various biases, a complementary approach, Mendelian randomization (MR), utilizes genetic variants as instrumental variables to approximate the lifetime status of exposure and enable causal inference in observational data. The random

allocation of the allele at conception and the natural directional effects of genetic

variants empower MR estimates to be less plaqued by confounding and reverse

Methods

Study design and data source

A two-sample MR study was conducted to examine the causal effects of 19 white blood cell traits on severe COVID-19. These blood cell traits were chosen based on a GWAS meta-analysis in 173,480 European ancestry individuals across three cohorts, and their summary statistics were available in the IEU OpenGWAS database [23, 24]. Genetic instruments for each white blood cell trait were chosen based on the following criteria: 1) $p < 8.31 \times 10^{-9}$ for association with the exposure; and 2) linkage disequilibrium (LD) clumping based on $r^2 > 0.001$. The data source and details for 19 white blood cell traits are available in Supplementary Table 1. The instrument-outcome effects were retrieved from the largest GWAS meta-analysis of COVID-19 to date, by the COVID-19 Host Genetics Initiative (HGI, release 3, accessed on July 2, 2020) [10]. We used the summary statistics based on the comparison of hospitalized COVID-19 patients (N = 3,199) with the general population (N = 897,488).

Statistical analysis

The causal effect of a white blood cell trait on severe COVID-19 was evaluated using the inverse variance-weighted (IVW) method with a multiplicative random-effects model [22, 25, 26]. Horizontal pleiotropy occurs when SNPs exert a direct effect on the severe COVD-19 through pathways other than the hypothesized exposure. To evaluate the possible presence of horizontal pleiotropy, we calculated Cochran's Q statistic for heterogeneity and conducted the intercept test associated with the MR-Egger method. Additional sensitivity analyses were performed with MR-Egger [22, 26], weighted

median (WM) [27], and Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test [28]. The MR-Egger estimates allowed directional or unbalanced horizontal pleiotropic effects. The weighted median method provides robust causal estimates even when up to 50 % SNPs are invalid genetic instruments [27]. The MR-PRESSO test was utilized to correct for the presence of specific horizontal pleiotropic outlier variants via detected outlier removal [28]. All MR analyses were conducted in R with the TwoSampleMR package [23].

Resources

- The COVID-19 Host Genetics Initiative: https://www.covid19hg.org/
- 114 The IEU OpenGWAS database: https://gwas.mrcieu.ac.uk/

Results

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

The counts of white blood cell, myeloid white blood cell, and granulocyte are negatively associated with severe COVID-19 By applying a two-sample MR approach, we first investigated the causal associations of the counts of white blood cell and its subpopulations with severe COVID-19. A relatively large number of independent SNPs, ranging from 79 for basophil count to 185 for monocyte count, were selected as genetic instruments for each blood cell count (Supplementary Tables 2-11). Based on the IVW MR estimates under a multiplicative random-effects model, we identified potentially causal, negative associations of white blood cell count (OR = 0.84, CI: 0.72-0.98, p = 0.031), basophil count (OR = 0.75, CI: 0.58-0.96, p = 0.023), myeloid white blood cell count (OR = 0.81, CI: 0.70-0.94, p =0.0070), and granulocyte count (OR = 0.84, CI: 0.71-0.99, p = 0.040) with severe COVID-19 (Fig. 1, Table 1). A suggestive negative association was also found for sum neutrophil eosinophil counts (OR = 0.85, CI: 0.73-1.00, p = 0.051). No evidence of heterogeneity in causal estimates was found by the Cochran Q statistic, and no evidence of horizontal pleiotropy was reported by the MR-Egger intercept test, except for basophil count (p = 0.036). Causal estimates from MR-Egger and WM MR revealed broadly concordant effect directions, although they are mostly not statistically significant, probably due to the reduced power of these two approaches [26] (Supplementary Fig. 1, Supplementary Table 21). MR-PRESSO analysis did not identify any outlier SNPs and yielded significant causal estimates for white blood cell count (p = 0.033), myeloid white blood cell count (p = 0.0078), and granulocyte count (p = 0.041) (Supplementary Table 21). Taken together, we demonstrated that white blood cell count, myeloid white blood

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

cell count, and granulocyte count had consistent, negative effects on the risk of severe COVID-19. The percentage of eosinophil in white blood cell is positively associated with severe COVID-19 We further investigated the causal associations of the percentages of specific white blood cells with severe COVID-19. As genetic instruments, we used 158 SNPs for eosinophil percentage, 63 SNPs for basophil percentage, 135 SNPs for the neutrophil percentage, 191 SNPs for monocyte percentage, and 135 SNPs for lymphocyte percentage (Supplementary Tables 12-16). Genetically predicted higher eosinophil percentage of white blood cells (OR = 1.22, CI: 1.03-1.45, p = 0.023) was associated with increased risk of severe COVID-19 using IVW with the random-effect model (Figure 1). The WM MR method and the MR-PRESSO analysis both revealed a consistent, positive effect (OR = 1.41, CI: 1.07-1.87, p = 0.015; and OR = 1.22, CI: 1.03-1.45, p = 0.024; respectively. Supplementary Table 21). No pleiotropy or outlier SNPs were identified in the MR-Egger test and MR-PRESSO analysis. Cochran Q statistics indicated no heterogeneity among the genetic instruments (Supplementary Table 21). The percentage of eosinophil in granulocyte is positively associated with severe COVID-19

We further focused on the granulocyte and evaluated if it specific compositions are associated with severe COVID-19. As genetic instruments, there were 168 SNPs for granulocyte percentage of myeloid white blood cells, 150 SNPs for eosinophil percentage of granulocytes, 59 SNPs for basophil percentage of granulocytes, and 141 SNPs for the neutrophil percentage of granulocytes (Supplementary Tables 17-20). Our results found suggestive evidence for a risk-increasing effect of eosinophil percentage of granulocytes on severe COVID-19 (OR = 1.18, CI: 1.00-1.39, p = 0.053). The WM MR method and the MR-PRESSO analysis both revealed a consistent positive effect (OR = 1.35, CI: 1.03-1.75, p = 0.029; and OR = 1.18, CI: 1.00-1.39, p = 0.055; respectively). No evidence of heterogeneity and pleiotropy was found. No statistically significant causal associations were identified for other specific granulocyte percentages (Figure 1 and Supplementary Table 21).

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

Discussion To our knowledge, this is the first MR study evaluating the causal roles of white blood cell traits in severe COVID-19 risk. Overall, our results suggest potential causal protective effects of increasing white blood cell count, myeloid white blood cell count, and granulocyte count on severe COVID-19. Our novel findings also include that genetically predicted higher eosinophil percentage in white blood cells or in granulocytes was associated with a higher risk of severe COVID-19. Previous observational studies have frequently pointed out increased white blood cell count in the severe COVID-19 patients, when compared to healthy controls or mild COVID-19 patients [1, 11, 12, 29]. However, there are also reports that normal or decreased white blood cell count is more common in COVID-19 patients when compared to the reference range or healty controls [10, 15-17, 30-32]. Our MR analysis showed that lower white blood cell count, myeloid white blood cell count, and granulocyte count may play a causal role in increasing the risk of severe COVID-19. The mechanism by which they contribute to severe COVID-19 remains unclear. Immune

system disorders have been suspected of playing roles in severe COVID-19 risk [33,

34]. The complete elucidation of the potential mechanism warrants further investigation.

Persistent eosinopenia after admission was associated with COVID-19 risk in previous retrospective and prospective observational studies [12, 15, 31, 32, 35-37]. There are also reports that eosinophil remains stable in severe COVID-19 patients [13, 29, 38, 39]. A multiparametric flow cytometry analysis found that high eosinophil count was

associated with an increased risk of severe COVID-19 [13]. Another observational study suggested that increasing eosinophil count might be an indicator of COVID-19 improvement [40]. Our MR analysis supported that high eosinophil percentage of white blood cells may be causal in increasing the risk of severe COVID-19 [40, 41], calling for future mechanistic studies.

Lymphopenia, as a response to viral infection, has been frequently associated with severe COVID-19 risk [1, 2, 13, 29, 41-51]. However, we did not detect a causal effect of lymphocyte count on severe COVID-19. This discrepancy may reflect reverse causality in retrospective and prospective observational studies, with depleted lymphocyte count as a result of immune response to SARS©CoV©2 infection [52]. Due to the limited number of SNPs associated with severe COVID-19, performing reverse MR analyses between severe COVID-19 and white blood cell traits is challenging. Using linkage disequilibrium (LD) assessment, only one SNP at locus 3p21.31 was retained in the previously published genome-wide significant SNPs [10]. We recently showed that SNPs at this locus are associated with multiple blood cell traits, suggesting they may have pleiotropic effects and are not suitable to be used as genetic instruments [53]. As more COVID-19-associated SNPs are identified in the future, reverse MR analysis will be valuable to understand the effect of COVID-19 on blood cell traits.

One assumption of MR is that the instrumental variable influences severe COVID-19 risk only through its effect on a specific white blood cell trait. The Cochran Q statistic did not reveal heterogeneity among our genetic instruments, and the MR-Egger intercept

test also indicated no presence of pleiotropic effects except those for basophil count. Our MR study was performed with strong instrumental variables and adequate statistical power, and we have conducted extensive sensitivity analyses. Still, we emphasize that our results should be interpreted with caution and future studies are needed to elucidate the mechanistic roles of white blood cell traits in severe COVID-19.

Conclusions

223

225

226

224 Our results suggest that lower white blood cell count, lower myeloid white blood cell

count, lower granulocyte count, and higher eosinophil percentage of white blood cells

are causally associated with an increased risk of severe COVID-19.

227 List of abbreviations COVID-19: coronavirus disease 2019 228 229 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2 230 MR: Mendelian randomization 231 GWAS: genome-wide association studies 232 SNPs: single nucleotide polymorphisms 233 LD: linkage disequilibrium 234 **HGI: Host Genetics Initiative** 235 IEU: Integrative Epidemiology Unit 236 IVW: inverse variance-weighted 237 WM: weighted median MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier 238

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

Declarations Ethics approval and consent to participate Ethical approval from the North West Multi-Centre Research Ethics Committee and written informed consent from all participants were obtained. **Consent for publication** Not applicable. Availability of data and materials All data generated or analyzed during this study are included in this published article and this supplementary information files. **Competing interests** The authors declare that they have no competing interests. **Funding** KY is supported by the University of Georgia Research Foundation. Funding sources had no involvement in the conception, design, analysis, or presentation of this work. **Authors' contributions** YS, JZ, and KY conceived the study. YS performed data analysis and prepared visualizations. YS, JZ, and KY interpreted the results. YS and KY wrote the first draft of

the manuscript. All authors critically read, revised, and approved the final version of the manuscript.

Acknowledgments

We would like to express our gratitude to all other Ye lab members for stimulating discussions.

References Uncategorized References

- 269 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al:
- 270 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
- Wuhan, China: a retrospective cohort study. *Lancet* 2020, **395**(10229):1054-1062.
- 272 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al:
- 273 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
- 274 Lancet 2020, **395**(10223):497-506.
- Wenham C, Smith J, Morgan R, Gender, Group C-W: **COVID-19: the gendered**
- 276 impacts of the outbreak. *Lancet* 2020, **395**(10227):846-848.
- 277 4. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM,
- 278 Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F *et al*: **COVID-19 and the**
- 279 cardiovascular system: implications for risk assessment, diagnosis, and
- 280 treatment options. Cardiovasc Res 2020, **116**(10):1666-1687.
- 5. Teng Y, Xu J, Zhang Y, Liu Z, Zhang S: **Mendelian randomization in COVID-19**:
- 282 Applications for cardiovascular comorbidities and beyond. EBioMedicine 2020,
- 283 **57**:102847.

- 284 6. Wu Z, McGoogan JM: Characteristics of and Important Lessons From the
- 285 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
- 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA
 287 2020.
- 288 7. Rao S, Lau A, So HC: Exploring Diseases/Traits and Blood Proteins
- 289 Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A
- 290 Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-
- 291 **Related Traits**. *Diabetes Care* 2020, **43**(7):1416-1426.
- 292 8. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere
- T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M et al:
- 294 Presence of Genetic Variants Among Young Men With Severe COVID-19. *JAMA* 295 2020.
- 296 9. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P,
- 297 Fernandez J, Prati D, Baselli G, Asselta R et al: Genomewide Association Study of
- 298 Severe Covid-19 with Respiratory Failure. N Engl J Med 2020.
- 299 10. Initiative C-HG: The COVID-19 Host Genetics Initiative, a global initiative to
- elucidate the role of host genetic factors in susceptibility and severity of the
- 301 **SARS-CoV-2 virus pandemic**. *Eur J Hum Genet* 2020, **28**(6):715-718.
- 302 11. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q et al:
- 303 Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-
- 304 **19 in Wuhan, China**. *JAMA Cardiol* 2020, **5**(7):802-810.
- 305 12. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W
- 306 et al: Dysregulation of Immune Response in Patients With Coronavirus 2019
- 307 **(COVID-19) in Wuhan, China**. *Clin Infect Dis* 2020, **71**(15):762-768.
- 308 13. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman
- 309 AR, Agyekum RS, Mathew D, Baxter AE, Vella LA et al: Comprehensive mapping of
- immune perturbations associated with severe COVID-19. Sci Immunol 2020, 5(49).
- 311 14. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R et al:
- 312 Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019
- coronavirus disease in the early stage. J Transl Med 2020, 18(1):206.

- 314 15. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M: The role of peripheral blood
- eosinophil counts in COVID-19 patients. *Allergy* 2020.
- 16. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH,
- Li CH et al: Clinical characteristics of novel coronavirus cases in tertiary hospitals
- in Hubei Province. Chin Med J (Engl) 2020, **133**(9):1025-1031.
- 17. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN,
- Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA: **Hematological findings**
- and complications of COVID-19. *Am J Hematol* 2020, **95**(7):834-847.
- 322 18. Siedlinski M, Jozefczuk E, Xu X, Teumer A, Evangelou E, Schnabel RB, Welsh P,
- 323 Maffia P, Erdmann J, Tomaszewski M *et al*: **White Blood Cells and Blood Pressure**:
- A Mendelian Randomization Study. Circulation 2020, 141(16):1307-1317.
- 325 19. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S et al: Viral
- and host factors related to the clinical outcome of COVID-19. *Nature* 2020,
- 327 **583**(7816):437-440.
- 328 20. Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, Zeng S, Ding X, Nie H: Clinical
- features in 52 patients with COVID-19 who have increased leukocyte count: a
- retrospective analysis. Eur J Clin Microbiol Infect Dis 2020.
- 21. Davies NM, Holmes MV, Davey Smith G: Reading Mendelian randomisation
- studies: a guide, glossary, and checklist for clinicians. *BMJ* 2018, **362**:k601.
- 333 22. Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M, Hartwig F,
- Holmes M, Minelli C, Relton C et al: Guidelines for performing Mendelian
- randomization investigations [version 2; peer review: 1 approved, 1 approved
- with reservations]. Wellcome Open Research 2020, 4(186).
- 337 23. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C,
- Burgess S, Bowden J, Langdon R et al: The MR-Base platform supports systematic
- causal inference across the human phenome. *Elife* 2018, **7**.
- 340 24. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H,
- Riveros-Mckay F, Kostadima MA et al: The Allelic Landscape of Human Blood Cell
- Trait Variation and Links to Common Complex Disease. Cell 2016, 167(5):1415-
- 343 1429 e1419.
- 344 25. Burgess S, Butterworth A, Thompson SG: Mendelian randomization analysis
- with multiple genetic variants using summarized data. Genet Epidemiol 2013,
- 346 **37**(7):658-665.
- 347 26. Bowden J, Davey Smith G, Burgess S: **Mendelian randomization with invalid**
- instruments: effect estimation and bias detection through Egger regression. Int J
- 349 *Epidemiol* 2015, **44**(2):512-525.
- 350 27. Bowden J, Davey Smith G, Haycock PC, Burgess S: Consistent Estimation in
- 351 Mendelian Randomization with Some Invalid Instruments Using a Weighted
- 352 **Median Estimator**. *Genet Epidemiol* 2016, **40**(4):304-314.
- 353 28. Verbanck M, Chen CY, Neale B, Do R: Detection of widespread horizontal
- 354 pleiotropy in causal relationships inferred from Mendelian randomization between
- 355 complex traits and diseases. *Nat Genet* 2018, **50**(5):693-698.
- 356 29. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD:
- 357 Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
- 358 *Allergy* 2020, **75**(7):1730-1741.

- 359 30. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, Sun R, Tian Z, Xu X, Wei H:
- Pathogenic T cells and inflammatory monocytes incite inflammatory storm in
- 361 **severe COVID-19 patients**. *Natl Sci Rev* 2020:nwaa041.
- 362 31. Sun DW, Zhang D, Tian RH, Li Y, Wang YS, Cao J, Tang Y, Zhang N, Zan T,
- 363 Gao L et al: The underlying changes and predicting role of peripheral blood
- inflammatory cells in severe COVID-19 patients: A sentinel? Clin Chim Acta 2020,
- 365 **508**:122-129.
- 366 32. Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, Xu L, Lei S, Pan A, Wang L et al:
- Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients
- in fever clinic: A retrospective case-control study. EClinicalMedicine 2020,
- 369 **23**:100375.
- 370 33. Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A,
- 371 Ostro R, Banovcin P: Immune Parameters and COVID-19 Infection Associations
- With Clinical Severity and Disease Prognosis. Front Cell Infect Microbiol 2020,
- 373 **10**:364.
- 374 34. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Bruggen MC,
- O'Mahony L, Gao Y, Nadeau K, Akdis CA: **Immune response to SARS-CoV-2 and**
- mechanisms of immunopathological changes in COVID-19. Allergy 2020,
- **75**(7):1564-1581.
- 378 35. Wang D, Li R, Wang J, Jiang Q, Gao C, Yang J, Ge L, Hu Q: **Correlation**
- analysis between disease severity and clinical and biochemical characteristics of
- 380 **143** cases of COVID-19 in Wuhan, China: a descriptive study. *BMC Infect Dis* 2020,
- **20**(1):519.
- 382 36. Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, Liu W, Tu S, Zhang M,
- Wang Q et al: Correlation Analysis Between Disease Severity and Inflammation-
- related Parameters in Patients with COVID-19 Pneumonia.
- 385 2020:2020.2002.2025.20025643.
- 386 37. Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH: Eosinopenia
- 387 and COVID-19. J Am Osteopath Assoc 2020.
- 388 38. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu
- 389 JG, Chen L et al: Epidemiologic and clinical characteristics of 91 hospitalized
- patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case
- 391 **series**. QJM 2020, **113**(7):474-481.
- 392 39. Lippi G, Henry BM: **Eosinophil count in severe coronavirus disease 2019**.
- 393 *QJM* 2020, **113**(7):511-512.
- 394 40. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J: Patients of
- 395 COVID-19 may benefit from sustained Lopinavir-combined regimen and the
- increase of Eosinophil may predict the outcome of COVID-19 progression. Int J
- 397 *Infect Dis* 2020, **95**:183-191.
- 398 41. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, Chen C, Pan Y, Hu X: **Abnormalities**
- of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin
- 400 *Chim Acta* 2020, **507**:174-180.
- 401 42. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle
- 402 L, Moreira A, Park MD et al. Immunology of COVID-19: Current State of the Science.
- 403 *Immunity* 2020, **52**(6):910-941.

- 404 43. Rothan HA, Byrareddy SN: The epidemiology and pathogenesis of
- 405 coronavirus disease (COVID-19) outbreak. *J Autoimmun* 2020, **109**:102433.
- 406 44. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong
- 407 Y et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
- 408 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020, **323**(11):1061-1069.
- 409 45. Ding Q, Lu P, Fan Y, Xia Y, Liu M: The clinical characteristics of pneumonia
- 410 patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan,
- 411 **China**. *J Med Virol* 2020.
- 412 46. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui
- 413 DSC et al: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J
- 414 *Med* 2020, **382**(18):1708-1720.
- 415 47. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D: **Early Clinical and CT**
- 416 Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. AJR Am J
- 417 Roentgenol 2020, **215**(2):338-343.
- 418 48. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J et
- 419 al: Clinical characteristics and imaging manifestations of the 2019 novel
- 420 coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang,
- 421 **China**. *J Infect* 2020, **80**(4):388-393.
- 422 49. Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL, Lin MG, Mu XD:
- 423 [Clinical features of 2019 novel coronavirus pneumonia in the early stage from a
- 424 **fever clinic in Beijing]**. *Zhonghua Jie He He Hu Xi Za Zhi* 2020, **43**(0):E013.
- 425 50. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX,
- 426 Huang K, Zeng QT: [Clinical characteristics and outcomes of 112 cardiovascular
- disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020,
- 428 **48**(6):450-455.

- 429 51. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong
- 430 Y et al: Clinical features and treatment of COVID-19 patients in northeast
- 431 **Chongging**. *J Med Virol* 2020, **92**(7):797-806.
- 432 52. Sattar N, Preiss D: Reverse Causality in Cardiovascular Epidemiological
- 433 Research: More Common Than Imagined? *Circulation* 2017, **135**(24):2369-2372.
- 434 53. Zhou J, Sun Y, Huang W, Ye K: **Altered blood cell traits underlie a major**
- 435 **genetic locus of severe COVID-19**. 2020:2020.2009.2009.20191700.

Tables

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

Table 1. Causal associations between white blood cell traits and severe COVID-19

based on random-effects IVW MR estimation.

Figure legends

Figure 1. Odds ratios for associations between genetically predicted risk factors and severe COVID-19. Analyses were done with the inverse variance-weighted (IVW) method with a multiplicative random-effects model. Effect estimates express the change in odds ratio (OR) per standard deviation (SD) increment in white blood cell traits, error bars indicate 95% confidence intervals. WBC#: White blood cell count; EO#: Eosinophil count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#: Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; BASO%: Basophil percentage of white blood cells; NEUT%: Neutrophil percentage of white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: Neutrophil percentage of granulocytes.

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

Supplemental Data Summary of GWAS information for white blood cell Supplementary Table 1. phenotypes Supplementary Table 2. 167 SNPs used IVs in MR analyses testing effect of white blood cell count on severe COVID-19 risk. Supplementary Table 3. 169 SNPs used IVs in MR analyses testing effect of eosinophil count on severe COVID-19 risk. Supplementary Table 4. 79 SNPs used IVs in MR analyses testing effect of basophil count on severe COVID-19 risk. Supplementary Table 5. 140 SNPs used IVs in MR analyses testing effect of neutrophil count on severe COVID-19 risk. Supplementary Table 6. 185 SNPs used IVs in MR analyses testing effect of monocyte count on severe COVID-19 risk. Supplementary Table 7. 160 SNPs used IVs in MR analyses testing effect of lymphocyte count on severe COVID-19 risk. Supplementary Table 8. 146 SNPs used IVs in MR analyses testing effect of myeloid white blood cell count on severe COVID-19 risk. Supplementary Table 9. 144 SNPs used IVs in MR analyses testing effect of granulocyte count on severe COVID-19 risk. Supplementary Table 10. 139 SNPs used IVs in MR analyses testing effect of sum neutrophil eosinophil counts on severe COVID-19 risk. Supplementary Table 11. 142 SNPs used IVs in MR analyses testing effect of sum

basophil neutrophil counts on severe COVID-19 risk.

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

Supplementary Table 12. 158 SNPs used IVs in MR analyses testing effect of eosinophil percentage of white blood cells on severe COVID-19 risk. Supplementary Table 13. 63 SNPs used IVs in MR analyses testing effect of basophil percentage of white blood cells on severe COVID-19 risk. Supplementary Table 14. 135 SNPs used IVs in MR analyses testing effect of neutrophil percentage of white blood cells on severe COVID-19 risk. Supplementary Table 15. 191 SNPs used IVs in MR analyses testing effect of monocyte percentage of white blood cells on severe COVID-19 risk. Supplementary Table 16. 135 SNPs used IVs in MR analyses testing effect of lymphocyte percentage of white blood cells on severe COVID-19 risk. Supplementary Table 17. 168 SNPs used IVs in MR analyses testing effect of granulocyte percentage of myeloid white blood cells on severe COVID-19 risk. Supplementary Table 18. 150 SNPs used IVs in MR analyses testing effect of eosinophil percentage of granulocytes on severe COVID-19 risk. Supplementary Table 19. 59 SNPs used IVs in MR analyses testing effect of basophil percentage of granulocytes on severe COVID-19 risk. Supplementary Table 20. 141 SNPs used IVs in MR analyses testing effect of neutrophil percentage of granulocytes on severe COVID-19 risk. Supplementary Table 21. MR estimates from each method of assessing the causal effects of white blood cells on severe COVID-19 risk. Supplementary Figure 1. Scatter plots of the genetic associations of white blood cell count (A), or myeloid white blood cell count (B), or granulocyte count (C), or basophil count (D) or eosinophil percentage in white blood cells (E) associated SNPs against the

genetic associations of severe COVID-19. The slopes of each line represent the causal association using different MR methods. The light blue line represents the random-effects inverse variance-weighted estimate, the dark blue line represents the MR-Egger estimate, and the green line represents the weighted median estimate.

Tables

Table 1. Causal associations between white blood cell traits and severe COVID-19 based on random-effects IVW MR estimation.

Exposure	Number	Odds ratio	95% CI	P-value	Heterogenity	MR-Egger intercept
	of SNPs				P-value	test P-value
WBC#	167	0.84	0.72, 0.98	0.031	0.847	0.406
EO#	169	1.15	0.98, 1.36	0.086	0.188	0.485
BASO#	79	0.75	0.58, 0.96	0.023	0.570	0.037
NEUT#	140	0.87	0.74, 1.04	0.119	0.804	0.631
MONO#	185	0.93	0.83, 1.06	0.285	0.592	0.714
LYMPH#	160	0.94	0.79, 1.12	0.486	0.145	0.875
MYELOID#	146	0.81	0.70, 0.94	0.0070	0.974	0.901
GRAN#	144	0.84	0.71, 0.99	0.040	0.868	0.378
(NEUT+EO)#	139	0.85	0.73, 1.00	0.051	0.941	0.470
(BASO+NEUT)#	142	0.87	0.74, 1.03	0.098	0.873	0.408
EO%	158	1.22	1.03, 1.45	0.023	0.209	0.808
BASO%	63	0.82	0.64, 1.05	0.122	0.821	0.063

135	1.15	0.94, 1.40	0.169	0.550	0.105
191	0.95	0.84, 1.08	0.457	0.656	0.388
135	1.06	0.87, 1.30	0.548	0.380	0.859
168	1.07	0.94, 1.22	0.325	0.894	0.746
150	1.18	1.00, 1.39	0.053	0.647	0.866
59	0.84	0.65, 1.09	0.182	0.768	0.117
141	0.85	0.71, 1.02	0.083	0.327	0.861
	191 135 168 150 59	191 0.95 135 1.06 168 1.07 150 1.18 59 0.84	191 0.95 0.84, 1.08 135 1.06 0.87, 1.30 168 1.07 0.94, 1.22 150 1.18 1.00, 1.39 59 0.84 0.65, 1.09	191 0.95 0.84, 1.08 0.457 135 1.06 0.87, 1.30 0.548 168 1.07 0.94, 1.22 0.325 150 1.18 1.00, 1.39 0.053 59 0.84 0.65, 1.09 0.182	191 0.95 0.84, 1.08 0.457 0.656 135 1.06 0.87, 1.30 0.548 0.380 168 1.07 0.94, 1.22 0.325 0.894 150 1.18 1.00, 1.39 0.053 0.647 59 0.84 0.65, 1.09 0.182 0.768

WBC#: White blood cell count; EO#: Eosinophil count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#: Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; NEUT%: Neutrophil percentage of white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: Neutrophil percentage of granulocytes.

